Skip to main content
OpenTrials
Completed

NCT Number: NCT04052958

DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1

For some diseases, regular respiratory muscle training could delay the start of ventilation. For DM1, however, there are no clinically high-quality studies. Only a case description from the year 2006 showed a missing improvement of the symptoms after respiratory muscle training in one patient, accordingly there are no recommendations in this issue. Within the scope of this monocentric, three-arm, controlled intervention study, 45 patients with genetically confirmed type 1 myotonic dystrophy will be randomized in three groups of 15 patients each, age-, gender- and symptom-corrected by the MUSCULAR IMPAIRMENT RATING SCALE (MIRS). The DM1 patients will receive regular respiratory muscle training for a period of 9 months. The aim of this study is to evaluate the safety and effectiveness of regular inspiratory strength-breathing muscle training on 15 patients, the safety and effectiveness of regular inspiratory endurance respiratory muscle training on 15 patients, and the comparison to the natural course in 15 patients without training. Subsequently, we will provide treatment recommendations for respiratory training in DM1.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myotonic Dystrophy 1 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Musculoskeletal Diseases Myotonic Disorders Myotonic Dystrophy Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany

Munich, Bavaria, 80336, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • the patient is willing and able to provide a signed informed consent form
  • the patient is ≥ 18 years old
  • the diagnosis of type 1 myotonic dystrophy has been confirmed by molecular genetics
  • the patient is able and willing to perform pulmonary function tests (PFT) and blood sampling for capillary blood gas analysis (pO2, pCO2) throughout the study, to keep a diary and to complete questionnaires

Exclusion criteria

  • the patient requires invasive ventilation (non-invasive ventilation is allowed).
  • the patient uses non-invasive ventilation more than 16h/day.
  • the patient participates in another clinical study that involves therapy.
  • the patient cannot perform pulmonary function tests (PFT).
  • the patient is diagnosed with central sleep apnea in polysomnography and not sufficiently treated with NIV ventilation.
  • the patient is diagnosed with obstructive sleep apnea and not sufficiently treated with NIV ventilation.
  • the patient cannot meet the requirements of the study, according to the investigator.
  • the patient is unable to complete a 6-minute walking test

Treatment and study plan

IMT - inspiratory muscle training

Device

respiratory strength or indurance training with respiratory therapy device

Primary outcomes

  1. Safety of recurrent inspiratory muscle training

    Time frame: nine months

    Intervention-related (serious) adverse events will be assessed as described in protocoll DM-IMT Version 1.2 (26/June/2019). For example a deterioration of > 15% of the FVC compared to the baseline measurements is defined as AE, as is the development of unusual myalgia of the respiratory muscles for more than 12 hours after the respiratory training. Detailed lists of patients experiencing adverse events or SAEs are reported. The severity of the adverse event is classified as mild, moderate or severe. Relationships of an AE to the training are categorized as unassociated, unlikely to be associated, possibly associated or associated. A separate list will be provided for patients who drop out of the study due to AEs. The frequency of adverse events leading to study termination is also summarized. Safety parameters also include lung function tests (PFT, including FVC, FEV1, MIP, MEP), physical examination, vital signs and clinical laboratory tests as required.

Secondary outcomes

  1. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by MIP.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Maximal inspiratory pressure (MIP).

  2. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by MIP.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Maximal inspiratory pressure (MIP).

  3. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by MEP.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Maximal exspiratory pressure (MEP).

  4. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by MEP.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Maximal exspiratory pressure (MEP).

  5. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by FVC.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Forced Vital capacity (FVC).

  6. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by FVC.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Forced Vital capacity (FVC).

  7. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by FEV1.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Forced Expiratory Volume in 1 second (FEV1).

  8. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by FEV1.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of Forced Expiratory Volume in 1 second (FEV1).

  9. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pCO2.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of pCO2 in capillary blood gas analysis.

  10. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pCO2.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of pCO2 in capillary blood gas analysis.

  11. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pO2.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of pO2 in capillary blood gas analysis.

  12. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pO2.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of pO2 in capillary blood gas analysis.

  13. Efficacy of recurrent inspiratory muscle strength training in 15 patients with type 1 myotonic dystrophy measured by pH.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of pH in capillary blood gas analysis.

  14. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by pH.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of pH in capillary blood gas analysis.

  15. Efficacy of recurrent inspiratory muscle endurance training in 15 patients with type 1 myotonic dystrophy measured by 6-minute-walk-test.

    Time frame: nine months

    The efficacy of the respiratory training is determined by the results of 6-minute-walk-test.

  16. Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by DM1-Activ.

    Time frame: nine months

    Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of DM1-ACTIV, a Rasch-built DM activity and participation scale for clinical use.

  17. Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by FDSS.

    Time frame: nine months

    Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the FDSS - FATIGUE AND DAYTIME SLEEPINESS SCALE, a Rasch-built combined fatigue and daytime sleepiness scale specifically designed for patients with DM1.

  18. Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by the questionnaire Respicheck.

    Time frame: nine months

    Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the RESPICHECK, a questionnaire on clinical symptoms of respiratory insufficiency.

  19. Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, measured by a physical examination.

    Time frame: nine months

    Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the physical examination.

  20. Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training compared to patients without training, using the 6-minute-walk-test.

    Time frame: nine months

    Impact on the quality of life and muscular performance in DM1 patients after recurrent respiratory muscle training will be measured by the result of the 6-minute-walk-test.

Sponsors and collaborators

Lead sponsor

LMU Klinikum

Other

Registry information

Acronym: DM-IMT

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Aug 12, 2019
Registry last updated
May 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.